Resistance to FGFR inhibitors in gastric cancer can arise through multiple mechanisms, including secondary mutations in the FGFR2 gene that prevent inhibitor binding, activation of compensatory signaling pathways such as MET and HER2, and changes in the tumor microenvironment that promote resistance. The gene discussed is ERBB2; the disease is gastric cancer.